Antibody-drug conjugate superstar ImmunoGen has signed another agreement to lend its targeted drug technology to Novartis for an undisclosed cancer therapy.
The report this week that Novartis' vaccine and diagnostic operation is one the company's execs might want to unload will not surprise employees at its Emeryville, CA, operation, where four dozen workers on the vaccine side have been given layoff notices.
It seemed like a match made in heaven. A few years ago, as the patent cliff neared and drugmakers were looking for new sources of revenue, market researchers were toting up growth prospects around...
Since breaking ground in Holly Springs, NC, in 2008, Novartis has repeatedly expanded the already ambitious scope of the cell culture vaccine site. Now, the Swiss drugmaker is adding a vaccine R&D laboratory in nearby Research Triangle Park (RTP).
The online chatter in Bloomberg and Reuters about potential Roche deals has been flying fast and furious recently, but there's been a streak of unfounded rumors that appear to be more smoke than fire.
News flash from Basel: Yes, Novartis really is considering selling off a few of its units, in deals that could be worth $15 billion to $20 billion. And no, Roche and Novartis aren't likely to embark on any big joint projects, much less consider a merger.
The day after showing that two of their respective therapies provided better results with earlier treatments, the companies followed up with analyses of safety and brain volume loss for their oral drugs, both of which have already gained significant market share in treating the disease.
Amgen and its partner AstraZeneca are headed to a scientific conference in Istanbul this weekend to lay out a slate of upbeat mid-stage data on a closely-watched psoriasis treatment now in Phase III. Top scientists at both companies say that the interleukin-17 targeting brodalumab continued to reflect the initial promise seen in the first round of Phase II data. And they'll be positioning the drug against a heavily competitive field that includes a heavyweight contender from Novartis.
Novartis pharma chief David Epstein isn't worried about Japanese sales of the blood pressure drug Diovan. He's "much more worried" about the Swiss drugmaker's reputation, now that its Diovan marketing and research are under investigation in Japan. And top-level Novartis managers in Japan are already feeling the effects of that concern.
Novartis' troubles in Japan just keep growing. Now, a government panel is zeroing in on its Diovan advertising. Officials say that the promos may have broken Japanese law--and that could lead to fines and jail terms, Bloomberg reports.